

## DAFTAR PUSTAKA

1. Hananta I.P.Y., Freitag H. Deteksi Dini dan Pencegahan Hipertensi dan Stroke. Yogyakarta: MedPress; 2011.
2. Depkes RI. Hipertensi Faktor Risiko Utama Penyakit Kardiovaskular. 2009;(Diakses pada 22 November 2021). Available from: <https://www.kemkes.go.id/article/print/157/hipertensi-faktor-risiko-utama-penyakit-kardiovaskular.html>
3. World Health Organization. Hypertension. 2021;(Diakses pada 22 November 2021). Available from: <https://www.who.int/news-room/fact-sheets/detail/hypertension>
4. Riset Kesehatan Dasar (Riskesdas). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018;(Diakses pada 22 November 2021).
5. Pubchem compound database.Captopril (Diakses pada 1 Desember 2021). Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Captopril>
6. N Tabibian, Albert L, E Alpert. Captopril-induced liver dysfunction. South Med J. 1987;
7. BPOM RI. Peraturan Badan Pengawas Obat Dan Makanan nomor 32 tahun 2019 Tentang Persyaratan Keamanan Dan Mutu Obat Tradisional. Jakarta: BPOM; 2019
8. Yam MF, Tan CS, Ruan Shibao. Vasorelaxant effect of sinensetin via the NO/sGC/cGMP pathway and potassium and calcium channels. Japanese Soc Hypertens. 2018;41(10):787–97.
9. Pusparini AD. Pengaruh Kandungan Seledri ( *Apium graveolens* L .) terhadap Penurunan Tekanan Darah pada Penderita Hipertensi. J Agromed Unila. 2015;2(3):290–5.
10. Rumiayati, Hakim AR, Winarti AD, Septia DN. Antihypertensive Testing Of Combination of *Apium graveolans* L., *Orthosiphon stamineus* Benth., and *Morinda citrifolia* Extract. On Normotensive And Hypertensive Sprague Dawley Rats. 2016;21(3):149–56.
11. Muyassar AM, Retnoningrum D. Pengaruh Ekstrak Daun Kumis Kucing (*Orthosiphon Aristatus*) Terhadap Fungsi Hepar Tikus Wistar Yang Diinduksi Plumbum Asetat. 2019;8(2):596–605.
12. Mutiarahmi CN, Hartady T, Lesmana R. Use of Mice As Experimental Animals in Laboratories That Refer To the Principles of Animal Welfare: a Literature Review. Indones Med Veterinus. 2021;10(1):134–45.
13. Suryaningsih et al. Pengaruh Kadar SGOT SGPT dan Morfologi Hepar Tikus Putih Betina Wistar Pada Pemberian Isolat *Andrographolide*. React Wkly. 2017;1620(1):26–26.
14. Susilo Y, Wulandari A. Cara Jitu Mengatasi Hipertensi. Yogyakarta:

- Penerbit Andi; 2011.
15. Ardiansyah M. Medikal Bedah. Yogyakarta: DIVA Press; 2012.
  16. Palimbong S. Keefektifan Diet Rendah Garam Pada Makanan Biasa Dan Lunak Terhadap Kesembuhan Hipertensi. *J Keperawatan Muhammadiyah*. 2018;3 No. 1.
  17. Jansen S. Makanan Fungsional. Yogyakarta: Kanisius; 2006.
  18. Triyanto E. Pelayanan keperawatan bagi penderita Hipertensi Secara Terpadu. Yogyakarta: Graha Ilmu; 2014.
  19. Husain K, Ansari RA, Ferder L. Alcohol-induced hypertension: Mechanism and prevention. *World J Cardiol*. 2014;6(5):245.
  20. Smeltzer SC, Bare BG. Keperawatan Medikal Bedah. Monica Este, editor. Jakarta: EGC; 2002.
  21. Wijaya, A.S dan Putri N. Keperawatan Medikal Bedah 2, Keperawatan Dewasa Teori dan Contoh Askep. In Yogyakarta: Nuha Medika; 2013.
  22. Matthew R Alexander, MD P. Hypertension. [emedicine.medscape.com](https://emedicine.medscape.com/article/241381-overview#a1) [Internet]. 2019;(Diakses pada 1 Desember 2021). Available from: <https://emedicine.medscape.com/article/241381-overview#a1>
  23. Anggraeni Y. Super Komplit Pengobatan Darah Tinggi. Yogyakarta: Araska; 2012.
  24. Smeltzer, Bare. Buku Ajar Keperawatan Medikal Bedah Brunner dan Suddarth. 8th ed. Jakarta: EGC; 2012.
  25. Denis L. Kasper, MD et al. Harrison's Principles of Internal Medicine 16th Edition. McGraw-Hill Companies Inc./; 2005. 1653 p.
  26. Huon H. Lecture notes cardiology Edisi 4. Jakarta: Erlangga Medical Series; 2002.
  27. Muttaqin, A & Sari K. Asuhan Keperawatan Gangguan Sistem Perkemihan. Jakarta: Salemba Medika; 2014.
  28. Aru W.Sudoyo dkk. Ilmu Penyakit Dalam FKUI. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam FKUI; 2006.
  29. Terence Potter, Schaefer. TJ. Hypertensive Encephalopathy. NCBI [Internet]. (Diakses pada 1 Desember 2021). Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554499/>
  30. Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A Pathophysiologic Approach. AIAA Guidance, Navigation, and Control Conference. 2015. 4485 p.
  31. Kementrian Kesehatan RI. Pelayanan Gizi Rumah Sakit ( PGRS). Jakarta: Kemenkes RI; 2013.
  32. Aspiani RY. Buku Ajar Asuhan Keperawatan Klien Gangguan



- Kardiovaskular Aplikasi NIC & NOC. Jakarta: EGC; 2015.
33. Nurrahmani U. Stop Hipertensi. Yogyakarta: Familia; 2012.
  34. Sanjai Sinha M. Captopril. Drugs.com [Internet]. (Diakses pada 5 Desember 2021). Available from: <https://www.drugs.com/captopril.html>
  35. Drugbank. Captopril. go.drugbank.com [Internet]. 2021;(Diakses pada 5 Desember 2021). Available from: <https://go.drugbank.com/drugs/DB01197>
  36. Yu Jie Chen , Liang Jin Li, Wen Lu Tang, Jia Yang Song, Ru Qiu, Qian Li, Hao Xue JMW. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. 2018;
  37. Varghese. Diabetic Nephropathy. StatPearls [Internet]. 2020; (Diakses pada 7 Desember 2021). Available from: <https://pubmed.ncbi.nlm.nih.gov/>
  38. Linda L. Herman, Padala SA, Ahmed I, Khalid Bashir. Angiotensin Converting Enzyme Inhibitors (ACEI). (Diakses pada 7 Desember 2021). Available from: <http://pubmed.ncbi.nlm.nih.gov/28613705/>
  39. Pusat Informasi Obat Nasional (Pionas). KAPTOPRIL. Badan Pengawas Obat dan Makanan Indonesia [Internet]. 2021;(Diakses pada 5 Desember 2021). Available from: <http://pionas.pom.go.id/monografi/kaptopril>
  40. D, Lezama-Martinez et al. Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems. [Internet]. 2018; Available from: <https://pubmed.ncbi.nlm.nih.gov/30422889/>
  41. Junior Lima Santos PC, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: Pharmacogenetic implications. *J Pharmacol Sci.* 2012;120(2):77–88.
  42. Duchin K., McKinstry DN, Cohen AJ, Migdaof BH. Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases. *Cinical Pharmacokinet* [Internet]. 2012;(Diakses pada 7 Desember 2021). Available from: <https://link.springer.com/article/10.2165%2F00003088-198814040-00002>
  43. Sonya GGordonMark DKittleson. Small Animal Clinical Pharmacology (Second Edition). In St. Louis, Missouri, USA.: Elsevier Saunders; 2008. p. 380–457.
  44. Lindle KA, Dinh K, Moffett BS, Kyle WB, Montgomery NM, Denfield SD KJ. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. *Pediatr Cardiol* [Internet]. 2014; Available from: <https://pubmed.ncbi.nlm.nih.gov/24233240/>
  45. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2018;(Diakses pada 7 Desember 2021). Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548504/>
  46. Anggraeni, D.L., Rusdi, B., Hilda A. Pengembangan Metode Analisis

Parasetamol dan Deksmetason Pada Jamu Pegal Linu Menggunakan Metode Ekstraksi Fasa Padat dan Kromatografi Cair Kinerja Tinggi. *Spes Unisba*. 2015;5(2):104–5.

47. Badan POM RI. Keputusan Kepala Badan Pengawas Obat dan Makanan. Nomor HK.00.05.4.2411 Tahun 2004 tentang Ketentuan Pokok Pengelompokan dan Penandaan Obat Bahan Alam Indonesia. Jakarta: BPOM RI; 2004.
48. Katno, Pramono S. Tingkat Manfaat dan Keamanan Tanaman Obat dan Obat Tradisional, Balai Penelitian Tanaman Obat Tawangmangu. Yogyakarta: UGM Fakultas Farmasi; 2006.
49. Klikdokter. Tensigard. 2020;(Diakses pada 20 Januari 2022). Available from: <https://www.klikdokter.com/obat/tensigard>
50. Anonim. Inventaris Tanaman Obat Indonesia (I) Jilid IV. Jakarta: Departemen Kesehatan dan Kesejahteraan Sosial Republik Indonesia; 2000. 173–174 p.
51. Adnyana et al. Ethnopharmacology to Clinical Study of *Orthosiphon stamineus* Benth. Bandung: Institut Teknologi Bandung; 2013.
52. Syamsiah et al. Tumbuhan Obat Tradisional. Sulawesi Barat: Alauddin University Press; 2016. 54 p.
53. Jie LH, Jantan R, Syaratul Dalina Yusoff JJ, Khairana Husain. Sinensetin: An Insight on Its Pharmacological Activities, Mechanisms of Action and Toxicity. 2020.
54. Omar Z, Salman MZ, Zaid O, Ibraheem, Yan MF, Ameer et al. *Orthosiphon stamineus*: Traditional Uses, Phytochemistry, Pharmacology and Toxicology. *J Med Food*. 2012;3–7.
55. Rukmana R. Bertanam Seledri. Yogyakarta: Kanisius; 2003.
56. Barnes. J. Anderson. A.L. PJD, Herbal Medicine Second edition. USA: Pharmaceutical Press; 2005.
57. Dalimartha S. Atlas Tumbuhan Obat Indonesia Volume ke-2. Jakarta: Trubus Agriwidya; 2000. 126–130 p.
58. Afifah MN. 8 Manfaat Seledri bagi Kesehatan Tubuh. *Health.kompas.com* [Internet]. 2020;(Diakses pada 31 Desember 2021). Available from: <https://health.kompas.com/read/2020/06/15/200300468/8-manfaat-seledri-bagi-kesehatan-tubuh?page=all>
59. Abdou, H. S, Salah, S. H, Hoda, B. F, and Abdel REA. Antioxidant Effect of Celery Against Carbontetrachloride Induced Hepatic Damage in Rats. *African J Microbiol Res*. 2012;(6(27)):5657–67.
60. Dalimartha S. Atlas Tumbuhan Obat Indonesia Jilid 3. Jakarta: Puspasua; 2003.



61. Pubchem compound database. Compound Summary for CID 5280443, Apigenin. Natl Cent Biotechnol Inf. 2022;(Diakses pada 2 Juni 2022).
62. Sudoyo AW. Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi V. Jakarta: Balai Penerbit FK UI; 2010.
63. Sloane E. Anatomi dan Fisiologi Untuk Pemula. Jakarta: Penerbit Buku Kedokteran EGC; 2004.
64. Netter FH. Atlas of Human Anatomy 4th Edition. Philadelphia: Saunders Elsevier; 2006.
65. Boyer TD, Manns MP SA. Zakim and Boyer's Hepatology : A textbook of Liver Disease 6th ed. Philadelphia: Saunders; 2012.
66. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW W, PA. Harper's Illustrated Biochemistry 28th ed. USA: McGraw-Hill's; 2009.
67. Irianto K. Epidemiologi Penyakit Menular dan Tidak Menular Panduan Klinis. Bandung: Alfabeta; 2013.
68. R.Juchau M, Hao Chen. Xenobiotic Biotransformation. In: Handbook of Developmental Neurotoxicology. Seattle, Washington: Department of Pharmacology School of Medicine University of Washington; 1998.
69. Stefan D, Hamilton JP. Drug-induced Liver Injury. [Internet]. 2011;73–80. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160634/>
70. Oda S, Yokoi T. Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms. Yakugaku Zasshi. 2015;135(4):579–88.
71. Sadikin M. Biokimia Enzim. Jakarta: Widya Medika; 2002.
72. Lowe D, Savio J, Terrence S. Alkaline Phosphatase. StatPearls [Internet]. 2021; (Diakses pada 2 Juni 2021). Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459201/>
73. Greiner. ALP-IFCC [Internet]. Bahlingen,Germany: Greiner; 2018. Available from: [www.greiner-diagnostic.com](http://www.greiner-diagnostic.com)
74. Aldi Y, Amdani A BA. Aktivitas Senyawa Skopoletin dari Buah Mengkudu (*Morinda citrifolia* Linn.) Terhadap Respon Fisiologi Makrofag Mencit Putih Jantan. Scient Journal Farm dan Kesehatan. 2016;
75. BPOM. Peraturan Badan Pengawas Obat Dan Makanan Nomor 18 Tahun 2021 Tentang Pedoman Uji Farmakodinamik Praklinik Obat Tradisional. Badan Pengawas Obat dan Makanan RI. 2021;(1):15–24.
76. Nirnanjan Banik, Adam Koesoemadinata, Charles Wagner, Charles Inyang HB. PMK No 43 tentang Penyelenggaraan Laboratorium Klinik Yang Baik. 2013;
77. Greiner. GPT/ALAT IFCC [Internet]. Bahlingen,Germany: Greiner; 2017. Available from: [www.greiner-diagnostic.com](http://www.greiner-diagnostic.com)



78. Yue S, Xue N, Li H, Huang B, Chen Z, Wang X. Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF- $\kappa$ B Pathway In Vivo and In Vitro. *Inflammation*. 2020;43(5):1634–48.
79. Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with Captopril therapy. *J Gastroenterol Hepatol*. 1991;6(5):528–30.
80. Ngatidjan. *Toksikologi: Racun, Keracunan, dan Terpai Keracunan*. Yogyakarta: Fakultas Kedokteran Universitas Gadjah Mada; 2006.
81. Yurista SR, Ferdian RA, Sargowo D. Prinsip 3Rs dan Pedoman ARRIVE Pada Studi Hewan Coba. *J Kardiologi Indones*. 2016;37(3):156–63.
82. Anonim. *Farmakope Indonesia Edisi III*. Jakarta: Departemen Kesehatan Republik Indonesia; 1979.
83. Nugroho RA. *Mengenal Mencit Sebagai Hewan Laboratorium*. Samarinda: Mulawarman University Press; 2018.
84. Burtis, C. A., Edward R. A. DAB. *Tietz Fundamental of Clinical Chemistry*. USA: Saunders; 2008.
85. Ronald AS. *Tinjauan Klinis Hasil Pemeriksaan Laboratorium*. Jakarta: Gramedia Pustaka Utama; 2004.
86. Schumann G, Klauke R, Canalias F, Bossert-Reuther S, Franck PFH, Gella FJ, et al. IFCC Reference procedure for the measurement of catalytic concentration of alkaline phosphatase International Federation of Clinical Chemistry. *Clin Chem Lab Med*. 2011;49(9):1439–46.
87. Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. *J Gastroenterol Hepatol*. 2017;32(7):1303–9.
88. HK W, WD H, JW H. *Clinical Methods: The History, Physical, and Laboratory Examinations*. 3rd edition. Boston: Butterworths; 1990.
89. Neal M. *At a Glance Farmakologi Medis Edisi Kelima*. Jakarta: Erlangga; 2006.
90. Sayuti K, Yenrina R. *Antioksidan Alami dan Sintetik*. Padang: Andalas Univesity Press; 2015.
91. Rana AC, Gulliya B. Chemistry and pharmacology of flavonoids-a review. *Indian J Pharm Educ Res*. 2019;
92. Parker W. Captopril-Induced Cholestatic Jaundice. *Core Top Cardiothorac Crit Care*. 1984;18:463–7.
93. Alshawsh MA, Abdulla MA, Ismail S, Amin ZA. Hepatoprotective Effects of *Orthosiphon stamineus* Extract on Thioacetamide-Induced Liver Cirrhosis in Rats. 2011;

